The short version of freeze-thaw fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-26. Anything still debated is marked as such rather than presented as settled.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
If insufficient quantities of copper are ingested, copper reserves in the liver will become depleted and a copper deficiency leading to disease or tissue injury (and in extreme cases, death). Toxicity from copper deficiency can be treated with a balanced diet or supplementation under the supervision of a doctor. On the contrary, like all substances, excess copper intake at levels far above World Health Organization limits can become toxic. Acute copper toxicity is generally associated with accidental ingestion. These symptoms abate when the high copper food source is no longer ingested. In 1996, the International Program on Chemical Safety, a World Health Organization-associated agency, stated "there is greater risk of health effects from deficiency of copper intake than from excess copper intake". This conclusion was confirmed in recent multi-route exposure surveys. The health conditions of non-genetic copper deficiency and copper excess are described below.
=== Development Tools === InSight Development Kits provide the hardware and software tools needed for application development. InSight Desktop allows for the programming and debugging of applications. It combines a packet sniffer, network analysis features, API tracing, and a virtual UART. InSight Adapter is used for network and microprocessor debugging and for programming chips. InSight USB Link is a FLASH programming device that connects to any PC via USB and to Ember’s Radio Control Module (RCM). It contains the hardware and software tools that read and write applications and program FLASH memory on the chips. AppBuilder makes network customization possible. It generates a template application that allows developers to tailor the EmberZNet PRO software to their specifications and complete the application, readying it for hardware integration and testing. It also allows configuration of the Hardware Abstraction Layer (HAL) and generates source code application with places for the developer to insert their own OEM-specific code. xIDE is a tool-chain that supports applications being written for the EM250. It has a C-language compiler, assembler, source-level debugger, and graphical editing environment.
=== Features === They are ovoid cells with granules. They have gastrin receptors. Some produce nesfatin-1. Ghrelin cells are not terminally differentiated in the pancreas: they are progenitor cells that can give rise to A-cells, PP cells and Beta-cells there.
== History == Lidocaine, the first amino amide–type local anesthetic (previous were amino esters), was first synthesized under the name 'xylocaine' by the team of chemist Nils Löfgren in 1943. Inga Fischer is credited for being the first to synthesize it at large-scale in the laboratory. Bengt Lundqvist performed the first injection anesthesia experiments on himself. It was first marketed in 1948 by Astra.
sovramagnificentissimamente (cited by Dante Alighieri in De vulgari eloquentia), 27 letters, "in a way that is more than magnificent by far" (archaic); incontrovertibilissimamente, 27 letters, "in a way that is very difficult to falsify"; particolareggiatissimamente, 27 letters, "in an extremely detailed way"; anticostituzionalissimamente, 28 letters, "in a way that strongly violates the constitution". The longest accepted neologism is psiconeuroendocrinoimmunologia (30 letters).. Other long words are:
Sources: en.wikipedia.org
=== Convenience, automation === In vitro methods can be miniaturized and automated, yielding high-throughput screening methods for testing molecules in pharmacology or toxicology. In toxicology, U.S. agencies such as the EPA use high-throughput in vitro screening to test large numbers of chemicals and reduce the need for animal-based toxicity tests.
== Adverse effects == Most of the comparatively few fatal incidents associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially alcohol. A common adverse effect resulting from psilocybin mushroom use involves "bad trips" or panic reactions, in which people become anxious, confused, agitated, or disoriented. Accidents, self-injury, or suicide attempts can result from serious cases of acute psychotic episodes. No studies have linked psilocybin with birth defects, but it is recommended that pregnant women avoid its usage.
== Classification == The MEROPS protease classification system counts 14 superfamilies plus several currently unassigned families (as of 2013) each containing many families. Each superfamily uses the catalytic triad or dyad in a different protein fold and so represent convergent evolution of the catalytic mechanism. For superfamilies, P indicates a superfamily containing a mixture of nucleophile class families, and C indicates purely cysteine proteases. Within each superfamily, families are designated by their catalytic nucleophile (C denoting cysteine proteases).
== Data analysis and chemometrics == The vast amount of data produced by modern analytical instruments has made computational data analysis an integral part of the field. The field of chemometrics uses statistical and mathematical methods to design optimal experimental procedures and to extract meaningful information from chemical data. Key areas include:
== Prelude == In November 2024, a coalition of rebel groups spearheaded by HTS attacked Aleppo, quickly overrunning the demotivated and disorganized defenders. In response, Assad travelled to Russia to ask for military aid on 28 November; his request was denied. Upon returning home, however, he lied to his senior commanders and advisors, claiming that Russia would soon send aid. His wife Asma had already been in Moscow for cancer treatment for months, accompanied by their children. A few days later, the rebels captured Aleppo. Afterward, reports emerged of a coup led by Syrian State Security Director General Hossam Louka against the Assad government. The Syrian Army General Command as well as the Iranian ambassador to Syria, Hossein Akbari, both denied these reports. On 2 December, Assad met with Iranian Foreign Minister Abbas Araghchi to discuss the situation. He confided that the Syrian Armed Forces were too weak to offer effective resistance to the continuing rebel advance. Regardless, he did not request increased Iranian aid, probably due to concerns about an Israeli intervention. At this point, the Syrian president had possibly concluded that the war was already lost. Despite this, he continued to tell his inner circle that Russian support would be coming, imploring them to continue their work. After the fall of Hama on 5 December, the government began redeploying its troops from Eastern Ghouta, including Douma and Harasta, to the entrances and exits of Damascus.
Sources: en.wikipedia.org
Possums, quolls and Tasmanian devils are facultatively necrophagous. For example, brushtail possums feed opportunistically on wild boar, kangaroo, pademelon and deer carrion, spotted-tailed quolls feed on kangaroo and pademelon carrion, and Tasmanian devils feed on possum, wallaby, kangaroo, wombat and pademelon carrion. Historically, quolls have also fed on human remains. Pademelon carrion is eaten frequently by Australian necrophages as pademelons are common in farming areas there, and often end up as roadkill. Brushtail possums eat carrion mostly in winter. This may be because there is less competition from necrophagous insects in winter, or because other food items such as leaves and fruit are more difficult to find. Quolls are also thought to scavenge mostly in winter, perhaps because they are hungriest in winter or because carrion is more readily available in winter.
ATP + β-D-ribosylnicotinate = ADP + nicotinate β-D-ribonucleotide In particular, it converts nicotinamide riboside into nicotinamide mononucleotide (NMN) and nicotinic acid riboside into nicotinic acid mononucleotide (NaMN). This reaction is part of one of the pathways of producing NAD+, but NMN can also be directly produced from nicotinamide through the action of the enzyme nicotinamide phosphoribosyltransferase (see Nicotinamide adenine dinucleotide § Biosynthesis for more details).
The failure of the January Uprising in Poland caused a major psychological trauma and became a historic watershed; indeed, it sparked the development of modern Polish nationalism. The Poles, subjected within the territories under the Russian and Prussian administrations to still stricter controls and increased persecution, sought to preserve their identity in non-violent ways. After the uprising, Congress Poland was downgraded in official usage from the "Kingdom of Poland" to the "Vistula Land" and was more fully integrated into Russia proper, but not entirely obliterated. The Russian and German languages were imposed in all public communication, and the Catholic Church was not spared from severe repression. Public education was increasingly subjected to Russification and Germanisation measures. Illiteracy was reduced, most effectively in the Prussian partition, but education in the Polish language was preserved mostly through unofficial efforts. The Prussian government pursued German colonization, including the purchase of Polish-owned land. On the other hand, the region of Galicia (western Ukraine and southern Poland) experienced a gradual relaxation of authoritarian policies and even a Polish cultural revival. Economically and socially backward, it was under the milder rule of the Austro-Hungarian Monarchy and from 1867 was increasingly allowed limited autonomy. Stańczycy, a conservative Polish pro-Austrian faction led by great land owners, dominated the Galician government. The Polish Academy of Learning (an academy of sciences) was founded in Kraków in 1872.
The balance-of-power system is discredited today. References to it, even by professional historians and international lawyers, commonly imply either that it was a system for war which repeatedly failed or that it was a system for making war which often succeeded in its purpose … During the period of its dominance as a European system, say, 1648 to 1918, its record in preventing war was certainly not striking. Indeed, it probably was itself responsible for starting more wars than it prevented. Former German Foreign Minister Joschka Fischer interpreted the core of the concept of Europe after 1945 as the rejection of the European balance-of-power principle and the hegemonic ambitions of individual states that had emerged following the Peace of Westphalia in 1648: "European integration was the response to centuries of a precarious balance of powers on this continent which again and again resulted in terrible hegemonic wars and culminated in the two World Wars between 1914 and 1945." Former US Secretary of Defense Dick Cheney expressed the same for Europe and other democracies: "It is not in our interest or those of the other democracies to return to earlier periods in which multiple military powers balanced one against another in what passed for security structures, while regional, or even global peace hung in the balance." NATO Secretary General, Manfred Wörner, outlined the European alternative at the end of the Cold War:
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.